Abstract
In this study we estimate the severity of the COVID-19 outbreak in Pakistan prior to and after lock down restrictions were eased. We also project the epidemic curve considering realistic quarantine, social distancing and possible medication scenarios. We use a deterministic epidemic model that includes asymptomatic, quarantined, isolated and medicated population compartments for our analysis. We calculate the basic reproduction number ℛ0 for the pre and post lock down periods, noting that during this time no medication was available.1 The pre-lock down value of ℛ0 is estimated to be 1.07 and the post lock down value is estimated to be 1.86. We use this analysis to project the epidemic curve for a variety of lock down, social distancing and medication scenarios. We note that if no substantial efforts are made to contain the epidemic, it will peak in mid of September, with the maximum projected active cases being close to 700,000. In a realistic, best case scenario, we project that the epidemic peaks in early to mid July with the maximum active cases being around 120000.We note that social distancing measures and medication if available will help flatten the curve, however without the reintroduction of further lock down it would be very difficult to bring ℛ0 below 1. Our study strongly supports the recent WHO recommendation of reintroducing lock downs to control the epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funds were available during this project
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Author email: mohsin_ali{at}lums.edu.pk
↵† Author email: mimran{at}asu.edu
1 Data data availability statement : The data that support the findings of this study are openly available in at COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University [https://github.com/CSSEGISandData/COVID-19], reference number [32].
Data Availability
https://github.com/CSSEGISandData/COVID-19
